{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T03:46:55Z","timestamp":1776743215748,"version":"3.51.2"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:00:00Z","timestamp":1760745600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.clml.2025.10.013","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:47:12Z","timestamp":1761007632000},"page":"e452-e459","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["New Zealand Multiple Myeloma Patients Demonstrate Inferior Outcomes When Compared to Australian Counterparts \u2013 A Retrospective Cohort Study from the Myeloma and Related Diseases Registry (MRDR)"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3769-7716","authenticated-orcid":false,"given":"Jian","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0758-3547","authenticated-orcid":false,"given":"Yayehirad","family":"Melsew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cameron","family":"Wellard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3881-6000","authenticated-orcid":false,"given":"Elizabeth M","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2811-8671","authenticated-orcid":false,"given":"P. Joy","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hang","family":"Quach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4555-6582","authenticated-orcid":false,"given":"Simon J","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2880-5088","authenticated-orcid":false,"given":"Rajeev","family":"Rajagopal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley","family":"Augustson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica M","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2025.10.013_bib0001","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2025.10.013_bib0003","series-title":"Myeloma New Zealand","article-title":"The burden of multiple myeloma - A study of the human and economic costs of myeloma in New Zealand","author":"Milne","year":"2019"},{"key":"10.1016\/j.clml.2025.10.013_bib0004","doi-asserted-by":"crossref","first-page":"103","DOI":"10.5694\/mja2.52366","article-title":"Multiple myeloma incidence, mortality, and prevalence estimates and projections, Australia, 1982-2043: a statistical modelling study","volume":"221","author":"Luo","year":"2024","journal-title":"Med J Austral"},{"key":"10.1016\/j.clml.2025.10.013_bib0005","doi-asserted-by":"crossref","first-page":"e670","DOI":"10.1016\/S2352-3026(22)00165-X","article-title":"The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends","volume":"9","author":"Huang","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2025.10.013_bib0006","doi-asserted-by":"crossref","first-page":"e762","DOI":"10.1016\/j.clml.2022.04.004","article-title":"M\u0101ori and Pacific peoples with multiple myeloma in New Zealand are younger and have inferior survival compared to other ethnicities: a study from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)","volume":"22","author":"Moore","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2025.10.013_bib0007","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.10.013_bib0008","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus Lenalidomide and Dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.10.013_bib0009","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s12874-016-0250-z","article-title":"Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry","volume":"16","author":"Bergin","year":"2016","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.clml.2025.10.013_bib0010","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1016\/j.clml.2021.01.016","article-title":"The myeloma landscape in Australia and New Zealand: the first 8 years of the Myeloma and Related Diseases Registry (MRDR)","volume":"21","author":"Bergin","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2025.10.013_bib0011","article-title":"R: A language and environment for statistical computing","year":"2023","journal-title":"R Foundation for Statistical Computing"},{"issue":"2","key":"10.1016\/j.clml.2025.10.013_bib0012","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1111\/ajco.13797","article-title":"The association of socioeconomic deprivation with access and survival after hematopoietic stem cell transplantation in New Zealand","volume":"19","author":"Belyaev","year":"2023","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.clml.2025.10.013_bib0013","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/bjh.16238","article-title":"Impact of age, sex, ethnicity, socio-economic deprivation and novel pharmaceuticals on the overall survival of patients with multiple myeloma in New Zealand","volume":"188","author":"Chan","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2025.10.013_bib0014","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.10.013_bib0015","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus Lenalidomide and Dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.10.013_bib0016","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1016\/j.clml.2024.08.007","article-title":"VCD versus VRD in newly diagnosed multiple myeloma: matched real-world analysis from the Balkan Myeloma Study Group (BMSG)","volume":"25","author":"Kastritis","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.clml.2025.10.013_bib0017","doi-asserted-by":"crossref","first-page":"69","DOI":"10.33590\/emjhematol\/20-00241","article-title":"Management of multiple myeloma in older patients","volume":"9","author":"Li","year":"2021","journal-title":"EMJ Hematol"},{"key":"10.1016\/j.clml.2025.10.013_bib0018","doi-asserted-by":"crossref","unstructured":"Lim SL, Reynolds J, Pemberton L, et al. Initial results from the frailty-stratified, randomised controlled Bayesian adaptive trial of Bortezomib versus Lenalidomide in Transplant Ineligible Myeloma (TI-NDMM) - the FRAIL-M Study (AMaRC 19-01; ALLG MM22). Blood 2024; 144:4755.","DOI":"10.1182\/blood-2024-209640"},{"key":"10.1016\/j.clml.2025.10.013_bib0019","doi-asserted-by":"crossref","DOI":"10.1177\/10732748231152330","article-title":"Comparison of cancer mortality and incidence between New Zealand and Australia and reflection on differences in cancer care: an ecological cross-sectional study of 2014-2018","volume":"30","author":"Aye","year":"2023","journal-title":"Cancer Control"},{"key":"10.1016\/j.clml.2025.10.013_bib0020","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1053\/j.seminoncol.2016.10.004","article-title":"Mind the gap: an analysis of foregone health gains from unfunded cancer medicines in New Zealand","volume":"43","author":"Evans","year":"2016","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clml.2025.10.013_bib0021","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1200\/JCO.21.02734","article-title":"Overall survival with Daratumumab, Bortezomib, and Dexamethasone in previously treated multiple myeloma (CASTOR): a randomized, open-label, Phase III Trial","volume":"41","author":"Sonneveld","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.10.013_bib0022","series-title":"Te rere o te toto \u2013 Understanding Blood Cancer Medicine Availability in Aotearoa New Zealand","article-title":"Full report","year":"2024"},{"key":"10.1016\/j.clml.2025.10.013_bib0023","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/bloodadvances.2023010026","article-title":"Final analysis of Carfilzomib, Dexamethasone, and Daratumumab versus Carfilzomib and Dexamethasone in the CANDOR study","volume":"7","author":"Usmani","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.10.013_bib0024","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/s41375-024-02505-2","article-title":"Daratumumab\/lenalidomide\/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes","volume":"39","author":"Facon","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2025.10.013_bib0025","doi-asserted-by":"crossref","first-page":"7272","DOI":"10.1182\/blood-2022-163483","article-title":"Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) alone in patients with Relapsed or Refractory Multiple Myeloma (RRMM): overall survival results from the Phase 3 Apollo Study","volume":"140","author":"Dimopoulos","year":"2022","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042491?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042491?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T03:18:20Z","timestamp":1776741500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025042491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2152265025042491"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.10.013","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New Zealand Multiple Myeloma Patients Demonstrate Inferior Outcomes When Compared to Australian Counterparts \u2013 A Retrospective Cohort Study from the Myeloma and Related Diseases Registry (MRDR)","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}